Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.
Autor*in: |
Iacovelli, Roberto [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2017 |
---|
Schlagwörter: |
---|
Umfang: |
48697 |
---|
Übergeordnetes Werk: |
Enthalten in: BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex - Siero, Jeroen C.W. ELSEVIER, 2014transfer abstract, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:35 ; year:2017 ; number:9 ; pages:5417-54113 ; extent:48697 |
Links: |
---|
DOI / URN: |
10.1016/j.urolonc.2017.05.007 |
---|
Katalog-ID: |
ELV030716446 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV030716446 | ||
003 | DE-627 | ||
005 | 20230623205911.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.urolonc.2017.05.007 |2 doi | |
028 | 5 | 2 | |a GBVA2017018000029.pica |
035 | |a (DE-627)ELV030716446 | ||
035 | |a (ELSEVIER)S1078-1439(17)30217-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Iacovelli, Roberto |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
264 | 1 | |c 2017 | |
300 | |a 48697 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. | ||
650 | 7 | |a Sunitinib |2 Elsevier | |
650 | 7 | |a Toxicity |2 Elsevier | |
650 | 7 | |a mRCC |2 Elsevier | |
650 | 7 | |a First-line |2 Elsevier | |
650 | 7 | |a Second-line |2 Elsevier | |
650 | 7 | |a Survival |2 Elsevier | |
650 | 7 | |a Pazopanib |2 Elsevier | |
650 | 7 | |a Dose reduction |2 Elsevier | |
700 | 1 | |a Cossu Rocca, Maria |4 oth | |
700 | 1 | |a Galli, Luca |4 oth | |
700 | 1 | |a De Giorgi, Ugo |4 oth | |
700 | 1 | |a Sabbatini, Roberto |4 oth | |
700 | 1 | |a Santoni, Matteo |4 oth | |
700 | 1 | |a Mosca, Alessandra |4 oth | |
700 | 1 | |a Fornarini, Giuseppe |4 oth | |
700 | 1 | |a Massari, Francesco |4 oth | |
700 | 1 | |a Masini, Cristina |4 oth | |
700 | 1 | |a Bersanelli, Melissa |4 oth | |
700 | 1 | |a Biasco, Elisa |4 oth | |
700 | 1 | |a Lolli, Cristian |4 oth | |
700 | 1 | |a Guida, Annalisa |4 oth | |
700 | 1 | |a Berardi, Rossana |4 oth | |
700 | 1 | |a Terrone, Carlo |4 oth | |
700 | 1 | |a Pastorino, Alessandro |4 oth | |
700 | 1 | |a Ardizzoni, Andrea |4 oth | |
700 | 1 | |a Pinto, Carmine |4 oth | |
700 | 1 | |a Buti, Sebastiano |4 oth | |
700 | 1 | |a Nolè, Franco |4 oth | |
700 | 1 | |a Tortora, Giampaolo |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Siero, Jeroen C.W. ELSEVIER |t BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |d 2014transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV012523860 |
773 | 1 | 8 | |g volume:35 |g year:2017 |g number:9 |g pages:5417-54113 |g extent:48697 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.urolonc.2017.05.007 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
951 | |a AR | ||
952 | |d 35 |j 2017 |e 9 |h 5417-54113 |g 48697 |y 35.2017, 9, 541.e7-, (48697 S.) | ||
953 | |2 045F |a 610 |
author_variant |
r i ri |
---|---|
matchkey_str |
iacovellirobertocossuroccamariagalliluca:2017----:lnclucmoptetwoeuesntnbraoaidrnfrtiera |
hierarchy_sort_str |
2017 |
publishDate |
2017 |
allfields |
10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610 |
spelling |
10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610 |
allfields_unstemmed |
10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610 |
allfieldsGer |
10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610 |
allfieldsSound |
10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610 |
language |
English |
source |
Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:35 year:2017 number:9 pages:5417-54113 extent:48697 |
sourceStr |
Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:35 year:2017 number:9 pages:5417-54113 extent:48697 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Sunitinib Toxicity mRCC First-line Second-line Survival Pazopanib Dose reduction |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
authorswithroles_txt_mv |
Iacovelli, Roberto @@aut@@ Cossu Rocca, Maria @@oth@@ Galli, Luca @@oth@@ De Giorgi, Ugo @@oth@@ Sabbatini, Roberto @@oth@@ Santoni, Matteo @@oth@@ Mosca, Alessandra @@oth@@ Fornarini, Giuseppe @@oth@@ Massari, Francesco @@oth@@ Masini, Cristina @@oth@@ Bersanelli, Melissa @@oth@@ Biasco, Elisa @@oth@@ Lolli, Cristian @@oth@@ Guida, Annalisa @@oth@@ Berardi, Rossana @@oth@@ Terrone, Carlo @@oth@@ Pastorino, Alessandro @@oth@@ Ardizzoni, Andrea @@oth@@ Pinto, Carmine @@oth@@ Buti, Sebastiano @@oth@@ Nolè, Franco @@oth@@ Tortora, Giampaolo @@oth@@ |
publishDateDaySort_date |
2017-01-01T00:00:00Z |
hierarchy_top_id |
ELV012523860 |
dewey-sort |
3610 |
id |
ELV030716446 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030716446</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623205911.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2017.05.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017018000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030716446</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(17)30217-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">48697</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mRCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">First-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pazopanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose reduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cossu Rocca, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galli, Luca</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Giorgi, Ugo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabbatini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fornarini, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Massari, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Masini, Cristina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bersanelli, Melissa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biasco, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lolli, Cristian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guida, Annalisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berardi, Rossana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terrone, Carlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pastorino, Alessandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ardizzoni, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pinto, Carmine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buti, Sebastiano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nolè, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tortora, Giampaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:5417-54113</subfield><subfield code="g">extent:48697</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2017.05.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2017</subfield><subfield code="e">9</subfield><subfield code="h">5417-54113</subfield><subfield code="g">48697</subfield><subfield code="y">35.2017, 9, 541.e7-, (48697 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Iacovelli, Roberto |
spellingShingle |
Iacovelli, Roberto ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
authorStr |
Iacovelli, Roberto |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012523860 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 610 VZ Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier |
topic |
ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction |
topic_unstemmed |
ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction |
topic_browse |
ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
r m c rm rmc l g lg g u d gu gud r s rs m s ms a m am g f gf f m fm c m cm m b mb e b eb c l cl a g ag r b rb c t ct a p ap a a aa c p cp s b sb f n fn g t gt |
hierarchy_parent_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
hierarchy_parent_id |
ELV012523860 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV012523860 |
title |
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
ctrlnum |
(DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X |
title_full |
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
author_sort |
Iacovelli, Roberto |
journal |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
journalStr |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2017 |
contenttype_str_mv |
zzz |
container_start_page |
5417 |
author_browse |
Iacovelli, Roberto |
container_volume |
35 |
physical |
48697 |
class |
610 610 DE-600 610 VZ |
format_se |
Elektronische Aufsätze |
author-letter |
Iacovelli, Roberto |
doi_str_mv |
10.1016/j.urolonc.2017.05.007 |
dewey-full |
610 |
title_sort |
clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
title_auth |
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
abstract |
To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. |
abstractGer |
To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. |
abstract_unstemmed |
To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
container_issue |
9 |
title_short |
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer |
url |
https://doi.org/10.1016/j.urolonc.2017.05.007 |
remote_bool |
true |
author2 |
Cossu Rocca, Maria Galli, Luca De Giorgi, Ugo Sabbatini, Roberto Santoni, Matteo Mosca, Alessandra Fornarini, Giuseppe Massari, Francesco Masini, Cristina Bersanelli, Melissa Biasco, Elisa Lolli, Cristian Guida, Annalisa Berardi, Rossana Terrone, Carlo Pastorino, Alessandro Ardizzoni, Andrea Pinto, Carmine Buti, Sebastiano Nolè, Franco Tortora, Giampaolo |
author2Str |
Cossu Rocca, Maria Galli, Luca De Giorgi, Ugo Sabbatini, Roberto Santoni, Matteo Mosca, Alessandra Fornarini, Giuseppe Massari, Francesco Masini, Cristina Bersanelli, Melissa Biasco, Elisa Lolli, Cristian Guida, Annalisa Berardi, Rossana Terrone, Carlo Pastorino, Alessandro Ardizzoni, Andrea Pinto, Carmine Buti, Sebastiano Nolè, Franco Tortora, Giampaolo |
ppnlink |
ELV012523860 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
doi_str |
10.1016/j.urolonc.2017.05.007 |
up_date |
2024-07-06T18:18:03.577Z |
_version_ |
1803854684961636352 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030716446</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623205911.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2017.05.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017018000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030716446</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(17)30217-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">48697</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mRCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">First-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pazopanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose reduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cossu Rocca, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galli, Luca</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Giorgi, Ugo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabbatini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fornarini, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Massari, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Masini, Cristina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bersanelli, Melissa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biasco, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lolli, Cristian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guida, Annalisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berardi, Rossana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terrone, Carlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pastorino, Alessandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ardizzoni, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pinto, Carmine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buti, Sebastiano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nolè, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tortora, Giampaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:5417-54113</subfield><subfield code="g">extent:48697</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2017.05.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2017</subfield><subfield code="e">9</subfield><subfield code="h">5417-54113</subfield><subfield code="g">48697</subfield><subfield code="y">35.2017, 9, 541.e7-, (48697 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.3994646 |